Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents

Clinical Infectious Diseases

Volumn 30, Issue 3, 2000, Pages 511-514

  Cinti, Sandro K ^a   Kaul, Daniel R ^a   Sax, Paul E ^b   Crane, Laurence R ^c   Kazanjian, Powel H ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL; LAMIVUDINE; NELFINAVIR; RIFABUTIN; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; BACTERIUM ISOLATION; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MYCOBACTERIOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RECURRENCE;

EID: 0034038464     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313705     Document Type: Article

References (28)

1. 1. Forrest DM, Seminari E, Hogg RS, et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiviral drugs. Clin Infect Dis 1998;27:1379-85.
2. 2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
3. 3. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998;351:252-5.
4. 4. Dworkin MS, Fratkin MD. Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS. Arch Intern Med 1998;158:1828.
5. 5. Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998;12:1491-4.
6. 6. French M, Lenzo N, John M, Mallel S, Price P, Flexman J. Immune restoration disease after treatment of immunodeficient HIV-infected patients with potent antiretroviral therapy [abstract 22323]. In: Conference record of the 12th International AIDS Conference (Geneva, Switzerland). Geneva: Marathon Multimedia, 1998.
7. 7. Furrer H, Malinverni R. Severe inflammatory reaction (SIR) after starting HAART in AIDS patients treated for disseminated tuberculosis: role of corticosteroids [abstract 22130]. In: Conference record of the 12th International AIDS Conference (Geneva, Switzerland). Geneva: Marathon Multimedia, 1998.
8. 8. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
9. 9. Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998;124:1815-22.
10. 10. Havlir D. Natural history of HIV-associated disease under HAART [presentation 629]. In: Conference record of the 12th International AIDS Conference (Geneva, Switzerland). Geneva: Marathon Multimedia, 1998:77.
11. 11. Aberg JA, Yajko DM, Jacobson MA. Eradication of disseminated Mycobacterium avium complex in four patients after twelve months anti-mycobacterial therapy and response to highly active antiretroviral therapy [abstract 729]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
12. 12. Egger M. Opportunistic infections in the era of HAART [abstract 77]. In: Conference record of the 12th International AIDS Conference (Geneva, Switzerland). Geneva: Marathon Multimedia, 1998.
13. 13. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
14. 14. Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998;27:1510-3.
15. 15. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998;351:256-61.
16. 16. Monsour HP Jr, Quigley EM, Markin RS, Dalke DD, Goldsmith JC, Harty RF. Endoscopy in the diagnosis of gastrointestinal Mycobacterium avium intracellulare infection. J Clin Gastroenterol 1991;13:20-4.
17. 17. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
18. 18. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351: 543-9.
19. 19. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
20. 20. Jones J, Hanson D, Dworkin M, Kaplan J. Which opportunistic illnesses occur in the era of HAART and at what CD4 cell count? [abstract 690]. In: Program and abstracts from the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
21. 21. Benson C. Immune reconstitution at the clinical interface [abstract S45]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
22. 22. Dworkin M, Hanson D, Jones J, Kaplan J. The risk for Pneumocystis carinii pneumonia (PCP) and disseminated nontuberculous mycobacteriosis after an antiretroviral-associated increase in the CD4 lymphocyte count [abstract 692]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
23. 23. Havlir DV, Schrier R, Torriani F, Chervenak K, Boon H. Reconstitution of M. avium complex immune responses after highly active antiretroviral therapy (HAART) [abstract 248]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
24. 24. Lederman HM, Von Reyn CF, Becker S, Williams P, Currier J. Improved immunologic function correlates with CD4 rise after highly active antiretroviral therapy [abstract 326]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
25. 25. Torriani FJ, Freeman WR, Karavellas M, et al. Lymphoproliferative responses to CMV predict CMV retinitis reactivation in patients who discontinued CMV maintenance therapy [abstract 250]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
26. 26. Schrier R, Torriani F, Durand D, Jeffrey D, Drew L, Lalazari J. Immune reconstitution of advanced HIV patients [abstract 325]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
27. 27. Autran B, Carcelain G, Tubiana R, et al. Effects of antiretroviral therapy on immune reconstitution [abstract S44]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
28. 28. Centers for Disease Control and Prevention. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with HIV. MMWR Morb Mortal Infect Dis 1999;48(RR-10):1-59, 61-6.